41.73

0.33% -0.14

Vericel Corp (VCEL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vericel Corp stock is traded at $41.73, with a volume of 974.01K. It is down -0.33% in the last 24 hours and down -5.67% over the past month. Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Previous Close:

$41.87

Open:

$41.78

24h Volume:

974.01K

Relative Volume:

2.03

Market Cap:

$1.95B

Revenue:

$226.84M

Net Income/Loss:

$3.55M

P/E Ratio:

596.14

EPS:

0.07

Net Cash Flow:

$-12.02M

1W Performance:

+7.14%

1M Performance:

-5.67%

6M Performance:

-22.72%

1Y Performance:

-14.22%

1-Day Range:

$41.37

$43.00

1-Week Range:

$37.48

$43.00

52-Week Range:

$37.39

$63.00

Vericel Corp Stock (VCEL) Company Profile

Name

Vericel Corp

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(734) 930-5555

Address

64 SIDNEY ST., CAMBRIDGE, MA

Employee

357

Twitter

@VericelCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

VCEL's Discussions on Twitter

Compare VCEL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCEL Vericel Corp	41.73	1.95B	226.84M	3.55M	-12.02M	0.07
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Vericel Corp Stock (VCEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-09-24	Initiated	Canaccord Genuity	Buy
Jun-20-24	Initiated	TD Cowen	Buy
Jan-25-24	Upgrade	Truist	Hold → Buy
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight
Sep-17-20	Initiated	Truist	Buy
Oct-09-19	Initiated	H.C. Wainwright	Buy
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-06-18	Reiterated	Needham	Buy
Mar-05-18	Reiterated	BTIG Research	Buy
Jun-21-17	Initiated	BTIG Research	Buy
Mar-13-17	Reiterated	Needham	Buy
Dec-22-16	Initiated	Piper Jaffray	Overweight
Nov-09-16	Reiterated	Needham	Buy
Apr-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Mar-11-16	Upgrade	Needham	Hold → Buy

View All

Vericel Corp Stock (VCEL) Latest News

02:07 AM

Vericel Corporation (NASDAQ:VCEL) Q1 2025 Earnings Call Transcript - Insider Monkey

02:07 AM

May 09, 2025

Vericel (VCEL) Maintains Buy Rating Despite Target Price Adjustment | VCEL Stock News - GuruFocus

May 09, 2025